相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Inclisiran and cardiovascular events: a patient-level analysis of phase III trials
Kausik K. Ray et al.
EUROPEAN HEART JOURNAL (2023)
Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial
Kausik K. Ray et al.
LANCET DIABETES & ENDOCRINOLOGY (2023)
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance
Marina Cuchel et al.
EUROPEAN HEART JOURNAL (2023)
Phase 2b Randomized Trial of the Oral PCSK9 Inhibitor MK-0616
Christie M. Ballantyne et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2023)
Novel and future lipid-modulating therapies for the prevention of cardiovascular disease
Julia Brandts et al.
NATURE REVIEWS CARDIOLOGY (2023)
Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients
S. E. E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30 months: Final results from the European observational HEYMANS study
Kausik K. Ray et al.
ATHEROSCLEROSIS (2023)
Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials
Paul Guedeney et al.
EUROPEAN HEART JOURNAL (2022)
Cholesteryl ester transfer protein inhibitors: from high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents?
Nick S. Nurmohamed et al.
CARDIOVASCULAR RESEARCH (2022)
Combination lipid-lowering therapy as first-line strategy in very high-risk patients
Kausik K. Ray et al.
EUROPEAN HEART JOURNAL (2022)
The dawn of a new era of targeted lipid-lowering therapies
Late Tokgozoglu et al.
EUROPEAN HEART JOURNAL (2022)
Highlights From the American Heart Association's Scientific Sessions-ApoB as a Risk Marker, an Oral PCSK9 Inhibitor, and Aspirin and Dementia
Jennifer Abbasi
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Gene Therapy Targeting PCSK9
Julius L. Katzmann et al.
METABOLITES (2022)
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?
Natalie C. Ward et al.
BIODRUGS (2022)
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials
Ulrich Laufs et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2022)
Effect of inclisiran on lipids in primary prevention: the ORION-11 trial
Kausik K. Ray et al.
EUROPEAN HEART JOURNAL (2022)
Bempedoic Acid: for Whom and When
Massimiliano Ruscica et al.
CURRENT ATHEROSCLEROSIS REPORTS (2022)
Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: a randomized phase 2 trial
Stephen J. Nicholls et al.
NATURE MEDICINE (2022)
Muscles and statins
[Anonymous]
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE (2022)
Paediatric patients with heterozygous familial hypercholesterolaemia treated with evolocumab for 80 weeks (HAUSER-OLE): a single-arm, multicentre, open-label extension of HAUSER-RCT
Raul Santos et al.
LANCET DIABETES & ENDOCRINOLOGY (2022)
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials
Cholesterol Treatment Trialists' Collaborators Collaborat et al.
LANCET (2022)
Moving toward genome-editing therapies for cardiovascular diseases
Kiran Musunuru
JOURNAL OF CLINICAL INVESTIGATION (2022)
Combination of bempedoic acid, ezetimibe, and atorvastatin in patients with hypercholesterolemia: A randomized clinical trial
John Rubino et al.
ATHEROSCLEROSIS (2021)
Long-term stable reduction of low-density lipoprotein in nonhuman primates following in vivo genome editing of PCSK9
Lili Wang et al.
MOLECULAR THERAPY (2021)
In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates
Kiran Musunuru et al.
NATURE (2021)
In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels
Tanja Rothgangl et al.
NATURE BIOTECHNOLOGY (2021)
An oral antisense oligonucleotide for PCSK9 inhibition
Peter Gennemark et al.
SCIENCE TRANSLATIONAL MEDICINE (2021)
Transcriptomic therapy for dyslipidemias utilizing nucleic acids targeted at ANGPTL3
Gerald F. Watts et al.
FUTURE CARDIOLOGY (2021)
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC)
Frank L. J. Visseren et al.
EUROPEAN HEART JOURNAL (2021)
PCSK9 vaccine: so near, yet so far!
Amirhossein Sahebkar et al.
EUROPEAN HEART JOURNAL (2021)
Angiopoietin-Like Protein 3 (ANGPTL3) Modulates Lipoprotein Metabolism and Dyslipidemia
Pei-Yi Chen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Inhibition of Angiopoietin-Like Protein 3 With Evinacumab in Subjects With High and Severe Hypertriglyceridemia
Zahid Ahmad et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2021)
Association between ANGPTL3, 4, and 8 and lipid and glucose metabolism markers in patients with diabetes
Marina Harada et al.
PLOS ONE (2021)
A VLP-based vaccine targeting ANGPTL3 lowers plasma triglycerides in mice
Alexandra Fowler et al.
VACCINE (2021)
Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia
Hirotaka Fukami et al.
CELL REPORTS MEDICINE (2021)
Cholesteryl ester transfer protein (CETP) as a drug target for cardiovascular disease
Amand F. Schmidt et al.
NATURE COMMUNICATIONS (2021)
PCSK9 immunization using nanoliposomes: preventive efficacy against hypercholesterolemia and atherosclerosis
Amir Abbas Momtazi-Borojeni et al.
ARCHIVES OF MEDICAL SCIENCE (2021)
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS)
Francois Mach et al.
EUROPEAN HEART JOURNAL (2020)
Long-Term Evolocumab in Patients With Familial Hypercholesterolemia
Raul D. Santos et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
PCSK9 inhibition with alirocumab in pediatric patients with heterozygous familial hypercholesterolemia: The ODYSSEY KIDS study
Stephen Daniels et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2020)
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia
Maciej Banach et al.
JAMA CARDIOLOGY (2020)
Efficacy and Safety of Alirocumab in Adults With Homozygous Familial Hypercholesterolemia The ODYSSEY HoFH Trial
Dirk J. Blom et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2020)
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia
Daniel Gaudet et al.
EUROPEAN HEART JOURNAL (2020)
Bempedoic acid safety analysis: Pooled data from four phase 3 clinical trials
Harold E. Bays et al.
JOURNAL OF CLINICAL LIPIDOLOGY (2020)
Evolocumab in Pediatric Heterozygous Familial Hypercholesterolemia
Raul D. Santos et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Evinacumab for Homozygous Familial Hypercholesterolemia
Frederick J. Raal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Evinacumab in Patients with Refractory Hypercholesterolemia
Robert S. Rosenson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
N-of-1 Trial of a Statin, Placebo, or No Treatment to Assess Side Effects
Frances A. Wood et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance
Ulrich Laufs et al.
JOURNAL OF THE AMERICAN HEART ASSOCIATION (2019)
Effect of 1 or 2 Doses of Inclisiran on Low-Density Lipoprotein Cholesterol Levels: One-Year Follow-up of the ORION-1 Randomized Clinical Trial
Kausik K. Ray et al.
JAMA CARDIOLOGY (2019)
Functional Analysis of LDLR (Low-Density Lipoprotein Receptor) Variants in Patient Lymphocytes to Assess the Effect of Evinacumab in Homozygous Familial Hypercholesterolemia Patients With a Spectrum of LDLR Activity
Poulabi Banerjee et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2019)
Lomitapide and Mipomersen-Inhibiting Microsomal Triglyceride Transfer Protein (MTP) and apoB100 Synthesis
Dirk J. Blom et al.
CURRENT ATHEROSCLEROSIS REPORTS (2019)
Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study
Christie M. Ballantyne et al.
ATHEROSCLEROSIS (2018)
Reduced Blood Lipid Levels With In Vivo CRISPR-Cas9 Base Editing of ANGPTL3
Alexandra C. Chadwick et al.
CIRCULATION (2018)
Meganuclease targeting of PCSK9 in macaque liver leads to stable reduction in serum cholesterol
Lili Wang et al.
NATURE BIOTECHNOLOGY (2018)
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
G. G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
RNA-targeted therapeutics for lipid disorders
Sotirios Tsimikas
CURRENT OPINION IN LIPIDOLOGY (2018)
PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
Matthew K. Ito et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Angiopoietin-like 3 in lipoprotein metabolism
Sander Kersten
NATURE REVIEWS ENDOCRINOLOGY (2017)
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Marc S. Sabatine et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia
Daniel Gaudet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol
Kausik K. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study
Frederick J. Raal et al.
LANCET DIABETES & ENDOCRINOLOGY (2017)
Long-term Low-Density Lipoprotein Cholesterol-Lowering Efficacy, Persistence, and Safety of Evolocumab in Treatment of Hypercholesterolemia Results Up to 4 Years From the Open-Label OSLER-1 Extension Study
Michael J. Koren et al.
JAMA CARDIOLOGY (2017)
Negative statin-related news stories decrease statin persistence and increase myocardial infarction and cardiovascular mortality: a nationwide prospective cohort study
Sune Fallgaard Nielsen et al.
EUROPEAN HEART JOURNAL (2016)
Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study
Frederick J. Raal et al.
ATHEROSCLEROSIS (2016)
Interpretation of the evidence for the efficacy and safety of statin therapy
Rory Collins et al.
LANCET (2016)
Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis
Stephen L. Pinkosky et al.
NATURE COMMUNICATIONS (2016)
Association of Lipid Fractions With Risks for Coronary Artery Disease and Diabetes
Jon White et al.
JAMA CARDIOLOGY (2016)
Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2015)
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Christopher P. Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
A cholesterol-lowering VLP vaccine that targets PCSK9
Erin Crossey et al.
VACCINE (2015)
A systematic review of statin-induced muscle problems in clinical trials
Harsha V. Ganga et al.
AMERICAN HEART JOURNAL (2014)
Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease
Nathan O. Stitziel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Peptide-Based Anti-PCSK9 Vaccines - An Approach for Long-Term LDLc Management
Gergana Galabova et al.
PLOS ONE (2014)
Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
Gregory G. Schwartz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity
Martin Jinek et al.
SCIENCE (2012)
Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia
Kiran Musunuru et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Major Lipids, Apolipoproteins, and Risk of Vascular Disease
The Emerging Risk Factors Collaboration*
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Immunodrugs: Therapeutic VLP-Based Vaccines for Chronic Diseases
Gary T. Jennings et al.
Annual Review of Pharmacology and Toxicology (2008)
Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia
John J. P. Kastelein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Effect of torcetrapib on the progression of coronary atherosclerosis
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)